Latest studies
- Ongoing, recruitingHuman Pharmacology (Phase I)- Bioequivalence Study
An open label, randomized, three-period, three-sequence, crossover bioavailability study to assess the pharmacokinetic and safety profile of Valacyclovir Oral Suspension compared to Valtrex® extemporaneous suspension in normal, healthy subjects under fasting conditions and to investigate the effect of food on the bioavailability of Valacyclovir Oral Suspension.
This study is testing a new liquid version of the medicine valacyclovir. It's comparing how well the new liquid is absorbed by the body compared to the usual liquid form. It will also check if food affects how the new liquid medicine works.
Not applicable (submitted trial is a bioequivalence study in healthy subjects)Czechia - RecruitingPHASE3
Maridebart Cafraglutide in Heart Failure With Preserved or Mildly Reduced Ejection Fraction and Obesity
This study looks at a new medicine, Maridebart cafraglutide, for people with heart failure and obesity. It aims to see if the medicine can reduce heart-related problems like hospital stays, improve symptoms, and help people live longer, alongside their usual heart failure care.
Heart Failure With Preserved Ejection FractionHeart Failure With Mildly Reduced Ejection FractionObesityCzechia - RecruitingPHASE3
Study to evaLuate the effIcacy and Safety of abeLacimab in High-risk Patients With Atrial Fibrillation Who Have Been Deemed Unsuitable for Oral antiCoagulation (LILAC-TIMI 76)
This study looks at a new medicine, abelacimab, for people with an irregular heartbeat (atrial fibrillation) who can't take usual blood thinners. It compares abelacimab to a dummy medicine to see if it can prevent strokes.
Atrial Fibrillation (AF)Czechia - Active not recruitingPHASE1
A Study of XL092 as Single-Agent and Combination Therapy in Subjects With Solid Tumors
This study looks at a new drug called XL092 for advanced solid tumours like kidney, breast, prostate, or bowel cancer. Researchers are testing it alone and with other drugs (Atezolizumab, Avelumab) to see if it's safe, how it works, and if it can help slow down or shrink tumours.
Neoplasm MalignantRenal Cell CarcinomaHormone Receptor Positive Breast CarcinomaMetastatic Castration-resistant Prostate CancerCzechia - Ongoing, recruitingTherapeutic confirmatory (Phase III)
A Phase 3, Open-Label, Long-Term Safety Extension Study Evaluating the Safety and Tolerability of the Fixed-Dose Combination of Obeticholic Acid and Bezafibrate in Subjects with Primary Biliary Cholangitis
This study looks at a new drug combination for Primary Biliary Cholangitis (PBC). It checks if mixing two existing medicines, Obeticholic Acid and Bezafibrate, helps liver health over a long time. Researchers want to see how safe and effective this combination is for patients.
Primary Biliary Cholangitis (PBC)Czechia - Active not recruitingPHASE3
Quizartinib or Placebo Plus Chemotherapy in Newly Diagnosed Patients With FLT3-ITD Negative AML
This study is looking at a new drug, quizartinib, combined with standard chemotherapy for adults recently diagnosed with a specific type of leukaemia called AML. We want to see if this combination improves treatment outcomes compared to chemotherapy alone.
LeukemiaCzechia - Recruiting
Lysosomal Acid Lipase (LAL) Deficiency Registry
This study is gathering information on a rare genetic condition called LAL Deficiency. It aims to understand the disease better and improve care for affected individuals, from babies to adults. It's a worldwide effort to collect health data over time.
Lysosomal Acid Lipase DeficiencyCholesterol Ester Storage DiseaseWolman DiseaseAcid Cholesteryl Ester Hydrolase Deficiency, Type 2Czechia - Active not recruitingPHASE3
A Study of Atezolizumab Versus Placebo as Adjuvant Therapy in Participants With High-risk Muscle-invasive Bladder Cancer (MIBC) Who Are ctDNA Positive Following Cystectomy
This study looks at a medicine called atezolizumab for people with a type of bladder cancer that has spread into the muscle. It checks if this medicine, given after surgery, can stop the cancer from coming back in those who show signs of tiny cancer cells in their blood.
Muscle-invasive Bladder CancerCzechia - Ongoing, recruitingTherapeutic confirmatory (Phase III)
A Phase 3, Randomized, Double-Masked, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy, Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Immunogenicity of Efgartigimod PH20 SC Administered by Prefilled Syringe in Adult Participants With Thyroid Eye Disease
This study is looking into a new treatment called Efgartigimod for Thyroid Eye Disease (TED). Researchers want to see how well it works, if it's safe, and if it causes any side effects. It's a big study involving many people, with some receiving the new drug and others a dummy treatment.
Thyroid Eye Disease (TED)Czechia - Ongoing, recruitingTherapeutic confirmatory (Phase III)
J2A-MC-GZGS: A Phase 3, Open-Label Study of Once Daily Orforglipron Compared with Insulin Glargine in Adult Participants with Type 2 Diabetes and Obesity or Overweight at Increased Cardiovascular Risk (ACHIEVE-4)
This study is testing a new medicine, Orforglipron, for adults with type 2 diabetes and who are overweight or obese. It's looking at how well it works compared to an insulin called Glargine to protect against heart problems.
Obesity, Chronic Kidney disease, Type 2 Diabetes, Cardiovascular Diseases, Overweight or Obesity, OverweightCzechia - Ongoing, recruitingTherapeutic exploratory (Phase II)
A Randomized Parallel-group, Placebo-controlled, Double-blind, Eventdriven, Multi-center Phase 2 Clinical Outcome Trial of Prevention of Arteriovenous Graft Thrombosis and Safety of MK-2060 in Patients With End Stage Renal Disease Receiving Hemodialysis
This study is testing a new medicine, MK-2060, to see if it can stop blood clots forming in special tubes (grafts) used for kidney dialysis. We want to know if it's safe and if it works better than a dummy medicine (placebo) for people with serious kidney disease.
Prevention of arteriovenous graft thrombosisCzechia - Ongoing, recruitingHuman Pharmacology (Phase I)- Other
A Phase 1/2 Multi-Center Study Evaluating the Safety and Efficacy of KTE-X19 in Pediatric and Adolescent Subjects with Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia or Relapsed/Refractory BCell Non Hodgkin Lymphoma (ZUMA-4)
This study is testing a new treatment called Tecartus for children and teenagers with certain types of blood cancer (leukaemia and lymphoma) that have come back after treatment. We want to see how safe it is and how well it works to help patients get better.
Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia (r/r ALL) Relapsed/Refractory B-cell non-Hodgkin lymphoma (r/r NHL)Czechia - Active not recruitingPHASE3
A Study of Baricitinib (LY3009104) in Participants From 1 Year to Less Than 18 Years Old With Systemic Juvenile Idiopathic Arthritis (sJIA)
This study is looking at a new medicine called baricitinib for children aged 1 to 17 with a type of arthritis called systemic juvenile idiopathic arthritis (sJIA). It aims to see if baricitinib is safe and helps to reduce their symptoms.
Systemic Juvenile Idiopathic ArthritisCzechia - Active not recruitingPHASE3
An Efficacy and Safety Study of Luspatercept (ACE-536) Versus Placebo in Subjects With Myeloproliferative Neoplasm-Associated Myelofibrosis on Concomitant JAK2 Inhibitor Therapy and Who Require Red Blood Cell Transfusions
This study looks at a new drug, Luspatercept, for people with myelofibrosis and anaemia who need regular blood transfusions and are already taking a JAK2 inhibitor. We want to see if it helps reduce the need for transfusions.
Myeloproliferative DisordersMyelofibrosisPrimary MyelofibrosisPost-Polycythemia Vera MyelofibrosisCzechia - Ongoing, recruitingTherapeutic exploratory (Phase II)
A Phase 2 Randomized Clinical Study of MK-4280A (coformulated favezelimab [MK-4280] plus pembrolizumab [MK-3475]) Versus Physician’s Choice Chemotherapy in PD-(L)1-refractory, Relapsed or Refractory Classical Hodgkin Lymphoma (KEYFORM-008)
This study is testing a new combination medicine (MK-4280A) against standard chemotherapy for people with Hodgkin Lymphoma that has come back or not responded to previous treatments. We want to see if the new medicine can stop the cancer from growing for longer.
Relapsed or Refractory Classical Hodgkin LymphomaCzechia - AuthorisedPhase II and Phase III (Integrated)
An International Prospective Study in Children Older than 3 to 5 Years with Clinically Standard-Risk Medulloblastoma with Low-Risk Biological Profile (PNET 5 MB – LR and PNET 5 MB – WNT-HR), average-risk biological profile (PNET 5 MB -SR), or TP53 mutation, and registry for MB ocurring in the context of genetic predisposition
This study is for children aged 3-18 with a type of brain tumour called medulloblastoma. It looks at different ways to treat the tumour, including various chemotherapy drugs, to find the most effective and safest options for different types of medulloblastoma, aiming to improve chances of recovery and quality of life.
MedulloblastomaCzechia - Ongoing, recruitingTherapeutic exploratory (Phase II)
J3P-MC-FTAF: An Adaptive Phase 2a/2b, Randomized, Double-Blind, Placebo-Controlled Study of LY3871801 in Adult Participants With Moderately-to-Severely Active Rheumatoid Arthritis
This study is testing a new medicine, LY3871801, for adults with rheumatoid arthritis. It's a research study to see how well the medicine works and if it's safe compared to a dummy pill. We hope to find new ways to help people with this condition.
Rheumatoid ArthritisCzechia - Ongoing, recruitingTherapeutic exploratory (Phase II)
A Phase II, Multicenter, Randomized, Double-Blind Study of Tobemstomig/RO7247669 Combined with Nab-Paclitaxel Compared with Pembrolizumab Combined with Nab-Paclitaxel in Participants with Previously Untreated, PD-L1-Positive, Locally-Advanced Unresectable or Metastatic Triple-Negative Breast Cancer
This study is testing a new combination of medicines for people with a type of breast cancer called triple-negative breast cancer that has spread or can't be removed with surgery. It aims to see if the new combination can help people live longer without their cancer getting worse.
Triple-Negative Breast Cancer (TNBC)Czechia - Active not recruitingPHASE3
Safety, Efficacy and Tolerability of Ianalumab Versus Placebo, Combination With SoC Therapy, in Participants With Active Lupus Nephritis
This study is testing a new medicine, ianalumab, for adults with active lupus nephritis. It compares ianalumab given every 4 or 12 weeks to a dummy medicine, alongside standard treatments, to see if it's safe and effective.
Lupus NephritisCzechia - RecruitingPHASE3
Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community- Acquired Pneumonia
This study, called REMAP-CAP, looks at different treatments for serious lung infections like pneumonia, flu, and COVID-19 in adults needing intensive care. It aims to find out which treatments work best to help patients recover.
Community-acquired Pneumonia, Influenza, COVID-19Czechia - Ongoing, recruitingHuman Pharmacology (Phase I)- Bioequivalence Study
Single dose, open-label, laboratory blinded, randomized, 2-treatment, 2-period, 2-sequence, crossover, pivotal study to assess the relative bioavailability of Test Product Naproxen sodium 660 mg modified release tablets to Reference Product Actromadol 660 mg Modified-Release tablets in healthy adult male and female subjects under fed conditions.
This study compares a new painkiller, similar to Actromadol, in healthy adults. We want to see if the new tablet works in the body similarly to the existing one after a meal. It's an important step before making new medicines widely available.
No medical conditionCzechia - Ongoing, recruitingPhase I and Phase II (Integrated)- First administration to humans
An Open-Label, Multicenter, Phase 1/2 Trial of GEN3014 (HexaBody®-CD38) in Relapsed or Refractory Multiple Myeloma and Other Hematologic Malignancies
This study is testing a new medicine, GEN3014, for people with multiple myeloma or other blood cancers that have come back or not responded to previous treatments. It aims to see if the medicine is safe and how well it works.
Relapsed or Refractory Multiple Myeloma (RRMM)Diffuse Large B Cell Lymphoma (DLBCL)Acute Myeloid Leukemia (AML)Czechia - RecruitingPHASE3
A Phase III Study of AZD0780 on Major Adverse CV Events in Patients With a History of ASCVD Events or at High Risk for a First Event
This study is looking into a new medication called AZD0780. It aims to see if this medicine can lower the risk of serious heart problems like heart attacks or strokes in people who have already had them, or in those at high risk of having one for the first time.
Cardiovascular DiseaseCzechia - RecruitingPHASE3
A Phase 3 Study of Etelcalcetide in Children With Secondary Hyperparathyroidism Receiving Hemodialysis
This study is looking at a new medicine called Etelcalcetide for children aged 2-17 with kidney disease who are on dialysis. It aims to see if the medicine works well and is safe for a condition called secondary hyperparathyroidism.
Secondary HyperparathyroidismCzechia - RecruitingPHASE2
A Study to Test Whether BI 1815368 Helps People With an Eye Condition Called Diabetic Macular Edema
This study tests a new medicine, BI 1815368, for people with diabetic macular edema (DME), an eye condition linked to diabetes. It aims to see if the medicine improves sight and to find the best dose. Participants take tablets for about 11 months.
Macular EdemaCzechia - Active not recruitingPHASE3
Study Comparing Blinatumomab Alternating With Low-intensity Chemotherapy Versus Standard of Care Chemotherapy for Older Adults With Newly Diagnosed Philadelphia-negative B-cell Precursor Acute Lymphoblastic Leukemia
This study looks at a new way to treat a type of leukaemia (blood cancer) called B-cell precursor acute lymphoblastic leukaemia (ALL) in older adults. It compares a drug called Blinatumomab combined with gentler chemotherapy against the usual chemotherapy treatment to see which works best.
Newly Diagnosed Philadelphia (Ph)-Negative B-cell Precursor Acute Lymphoblastic Leukemia (ALL)Czechia - RecruitingPHASE3
A Study to Evaluate the Efficacy of Pumitamig Versus Pembrolizumab in Participants With Previously Untreated Advanced Non-Small Cell Lung Cancer and PD-L1 ≥ 50%. (ROSETTA Lung-202)
This study looks at a new treatment called Pumitamig for advanced non-small cell lung cancer that hasn't been treated before. It compares Pumitamig to an existing treatment, Pembrolizumab, in people whose cancer cells have a high level of a specific marker called PD-L1.
Non-Small Cell Lung Cancer (NSCLC)Czechia - RecruitingPHASE2, PHASE3
(HARBOR) Study to Evaluate Efficacy and Safety of BLU-263 Versus Placebo in Patients With Indolent Systemic Mastocytosis
This study is testing a new medicine, elenestinib, for a rare blood condition called indolent systemic mastocytosis. It compares the new medicine to a dummy pill (placebo) to see if it helps reduce symptoms that current treatments aren't fully controlling.
Indolent Systemic MastocytosisSmoldering Systemic MastocytosisCzechia - RecruitingPHASE3
Phase III Study of Ivonescimab or Bevacizumab Combined With FOLFOX in Patients With Metastatic Colorectal Cancer
This study is testing a new drug called ivonescimab for bowel cancer that has spread. It compares ivonescimab with a standard treatment, bevacizumab, both given alongside regular chemotherapy. The aim is to see if ivonescimab works better as a first treatment.
Metastatic Colorectal Cancer (CRC)Czechia - RecruitingPHASE3
Study of Casdatifan and Cabozantinib Versus Placebo and Cabozantinib in Patients With Advanced Clear Cell Renal Cell Carcinoma
This study is looking at a new drug, casdatifan, combined with an existing one, cabozantinib, for advanced clear cell kidney cancer. It compares this combination to cabozantinib with a dummy drug (placebo) to see if it stops cancer growth for longer in patients who've already had immunotherapy.
Metastatic Clear Cell Renal Cell CarcinomaAdvanced Clear Cell Renal Cell CarcinomaCzechia - Ongoing, recruitingTherapeutic confirmatory (Phase III)
(22153) Randomized, Double-Masked, Active-Controlled, Phase 3 Study of the Efficacy and Safety of Aflibercept 8 mg in Macular Edema Secondary to Retinal Vein Occlusion
This study looks at a new version of Eylea (a medicine for eye problems) to see if it's safe and works well for people with blurry vision caused by fluid build-up at the back of their eye. It compares the new version to the standard treatment.
Macular edema secondary to retinal vein occlusionCzechia - Active not recruitingPHASE3
Linerixibat Long-term Safety, and Tolerability Study
This study looks at the long-term safety of a medicine called linerixibat for people with cholestasis, a liver condition that can cause severe itching. It's for patients who have already tried linerixibat in previous studies.
CholestasisCzechia - Active not recruitingPHASE3
Phase 3 Study of MRTX849 With Cetuximab vs Chemotherapy in Patients With Advanced Colorectal Cancer With KRAS G12C Mutation (KRYSTAL-10)
This study, KRYSTAL-10, is for people with advanced bowel cancer that has a specific genetic change (KRAS G12C). It compares a combination of new drugs, MRTX849 and cetuximab, against standard chemotherapy to see which works better for those who have already had initial treatment.
Advanced Colorectal CancerMetastatic Colorectal CancerCzechia - Active not recruitingPHASE3
A Comparative Study of AZD9833 Plus Palbociclib Versus Anastrozole Plus Palbociclib in Patients With ER-Positive HER2 Negative Breast Cancer Who Have Not Received Any Systemic Treatment for Advanced Disease
This study compares two drug combinations – camizestrant with palbociclib, and anastrozole with palbociclib – for advanced breast cancer. It's for patients whose cancer has specific hormone features and hasn't yet been treated for its advanced stage. The goal is to find a better first treatment.
ER-Positive HER2-Negative Breast CancerCzechia - Active not recruitingPHASE3
Capivasertib+Paclitaxel as First Line Treatment for Patients With Locally Advanced or Metastatic TNBC
This study is looking into a new combination treatment for a type of breast cancer called triple-negative breast cancer (TNBC) that has spread or is advanced. It combines a new drug, Capivasertib, with a common chemotherapy, Paclitaxel, to see if it works better than just Paclitaxel alone.
Triple Negative Breast NeoplasmsCzechia - RecruitingPHASE3
A Study of Vepugratinib (LY3866288) in Participants With Cancer in the Urinary Tract
This study is testing a new medicine, vepugratinib, for advanced or spread bladder cancer. It will be given with two other drugs, enfortumab vedotin and pembrolizumab, to see if it's safe and helps. It’s compared to a dummy medicine (placebo).
Carcinoma, Transitional CellUrinary Bladder NeoplasmsNeoplasm MetastasisCzechia - Ongoing, recruitingTherapeutic confirmatory (Phase III)
A randomized, parallel-group, 24 week, double-blind, placebo-controlled, multicenter Phase 3 study to assess the efficacy and safety of secukinumab compared to placebo in adult patients with active rotator cuff tendinopathy
This study is testing a new medicine, secukinumab, for people with ongoing shoulder pain caused by rotator cuff problems. It compares the medicine to a dummy treatment (placebo) to see if it helps reduce pain and improve shoulder movement over 24 weeks.
Moderate to severe rotator cuff tendinopathyCzechia - Ongoing, recruitingPhase I and Phase II (Integrated)- Other
An Open-Label Extension of Study HGT-MLD-070 Evaluating Long Term Safety and Efficacy of Intrathecal Administration of HGT-1110 in Patients with Metachromatic Leukodystrophy
This study is looking at a new treatment called rhASA for a rare genetic condition in children and young people called Metachromatic Leukodystrophy (MLD). It's checking if the treatment is safe and if it helps with MLD symptoms over a long time.
Late Metachromatic Leukodystrophy (MLD)Czechia - Active not recruitingPHASE3
A Study to Evaluate the Efficacy, Safety, and Tolerability of BMS-986278 in Participants With Progressive Pulmonary Fibrosis
This study is looking into a new medication called BMS-986278 for people with progressive pulmonary fibrosis. It aims to see if the medication is safe and effective in slowing down this lung condition.
Progressive Pulmonary FibrosisCzechia - AuthorisedTherapeutic confirmatory (Phase III)
A Phase 3b, Multicenter, Randomized, Open-Label, Active-Controlled Study to Compare the Efficacy and Safety of Guselkumab versus Risankizumab in the Treatment of Participants with Moderately to Severely Active Crohn’s Disease
This study compares two existing medicines, Guselkumab and Risankizumab (also known as Skyrizi), for adults with Crohn's disease that is moderate to severe. It aims to see which medicine works better and is safer over time to help people feel much better.
Moderately to Severely Active Crohn’s DiseaseCzechia - RecruitingPHASE3
Pembrolizumab With or Without Maintenance Sacituzumab Tirumotecan (Sac-TMT; MK-2870) in Metastatic Squamous Non-small Cell Lung Cancer (NSCLC) [MK-2870-023]
This study looks at new ways to treat advanced squamous non-small cell lung cancer. It combines standard treatment (Pembrolizumab, Carboplatin, Paclitaxel/Nab-paclitaxel) with a new drug, sac-TMT, to see if it helps people live longer.
Non-small Cell Lung CancerNSCLCCzechia - Active not recruitingPHASE2, PHASE3
Long-Term Safety and Efficacy Evaluation of Amlitelimab in Participants of Previous Amlitelimab Moderate to Severe Atopic Dermatitis Clinical Trials
This study looks at a medicine called amlitelimab for moderate to severe eczema in people who've already tried it in other studies. We want to see how safe and effective it is over a long time, and if it continues to help.
Dermatitis AtopicCzechia - Active not recruitingPHASE3
A Study to Evaluate Efficacy and Safety of Tulisokibart (MK-7240) in Participants With Moderately to Severely Active Ulcerative Colitis (MK-7240-001)
This study is testing a new medicine, tulisokibart, for people with moderate to severe ulcerative colitis. It aims to see if the medicine can help people feel better and stay in remission, compared to a dummy medicine, both in the short and long term.
Ulcerative ColitisCzechia - Active not recruitingPHASE3
Efficacy and Safety Studies of Frexalimab (SAR441344) in Adults With Relapsing Forms of Multiple Sclerosis
This study is looking at a new medicine called frexalimab for people aged 18-55 with certain types of Multiple Sclerosis (MS). It compares frexalimab to an existing MS medicine, teriflunomide, to see how well it stops MS relapses and if it's safe.
Multiple SclerosisCzechia - Active not recruitingPHASE3
A Study to Evaluate the Treatment Response and Safety of Two Dose Regimens of Subcutaneous Amlitelimab Compared With Treatment Withdrawal in Participants Aged 12 Years and Older With Moderate-to-severe Atopic Dermatitis
This study is testing a new medicine, Amlitelimab, for moderate-to-severe eczema in people aged 12 and over. It's looking at how well different doses work and if they're safe, compared to stopping treatment.
Dermatitis AtopicCzechia - Enrolling by invitationPHASE3
A Study to Assess the Long-term Safety and Efficacy of a Subcutaneous Formulation of Efgartigimod in Adults With Active Idiopathic Inflammatory Myopathy
This study looks at a new medicine called efgartigimod for people with certain muscle conditions like myositis. It's for adults who were in a previous study, to see if the medicine is safe and helpful over a long time.
MyositisActive Idiopathic Inflammatory MyopathyDermatomyositisPolymyositisCzechia - RecruitingPHASE3
A Study to Evaluate the Efficacy and Safety of Remibrutinib in Secondary Progressive Multiple Sclerosis
This study is looking into a new medication called remibrutinib for people with a type of multiple sclerosis (MS) called Secondary Progressive MS (SPMS). It will check if the medicine is safe and helps slow down the disease.
Secondary Progressive Multiple Sclerosis (SPMS)Czechia - Ongoing, recruitingPhase I and Phase II (Integrated)- Other
A5481092: PHASE 1/2 STUDY TO EVALUATE PALBOCICLIB (IBRANCE®) IN COMBINATION WITH IRINOTECAN AND TEMOZOLOMIDE OR IN COMBINATION WITH TOPOTECAN AND CYCLOPHOSPHAMIDE IN PEDIATRIC PATIENTS WITH RECURRENT OR REFRACTORY SOLID TUMORS
This study looks at new drug combinations for children with specific types of cancer (Ewing sarcoma or neuroblastoma) that have come back or not responded to previous treatment. It tests how safe and effective these combinations are.
recurrent/refractory Ewing sarcoma, recurrent or refractory neuroblastomaCzechia - Active not recruitingNA
First in Human Clinical Investigation of the FIRE1 System in Heart Failure Patients (FUTURE-HF)
This study is testing a new device, the FIRE1 System, for people with heart failure. It will involve up to 50 patients to see if the device can be safely put into the body and if it works as intended. We want to understand how it could help manage heart failure.
Heart FailureCzechia - Active not recruitingPHASE3
Phase 3, Double-blind, Randomized, Placebo-controlled Trial to Evaluate the Efficacy and Safety of AR1001 in Participants With Early Alzheimer's Disease (Polaris-AD)
This study is testing a new medicine, AR1001, for people in the early stages of Alzheimer's disease. We want to see if it's safe and helps improve or slow down symptoms compared to a dummy medicine.
Alzheimer DiseaseCzechia